Semler Scientific, Inc.

Semler Scientific, Inc. develops and markets technology products and services to help customers evaluate and treat chronic diseases. The company's primary product is QuantaFlo, a patented and FDA-cleared device that measures arterial blood flow in the extremities to assist in diagnosing Peripheral Artery Disease (PAD). Semler Scientific is also seeking a new 510(k) clearance from the FDA to expand QuantaFlo's use and labeling to aid in diagnosing other cardiovascular diseases in addition to PAD. The company's healthcare technology solutions business is its main operational focus, generating cash flows that support its overall strategy. Semler Scientific also invests in bitcoin, which it adopted as its primary treasury reserve asset in May 2024, subject to market conditions and anticipated cash needs. Cash flows from operations, along with proceeds from equity and debt financings, are used to accumulate bitcoin. Semler Scientific continues to develop additional proprietary products internally and seeks other arrangements for products and services to provide value to its customers. For the year ended December 31, 2024, the company reported total revenues of $56.3 million and net income of $40.9 million. This compares to total revenues of $68.2 million and net income of $20.6 million in 2023.